Abstract
We describe the case of a 13-year-old boy with stage I hypopigmented mycosis fungoides in whom minimal residual disease was detected with T-cell receptor gamma-polymerase chain reaction after the disease was in complete clinical remission. We further cloned and sequenced the T-cell receptor gamma-polymerase chain reaction product of the lesion in remission and found that the original T-cell clone still existed in decreased amounts. The patient was followed up for 3 1/2 years without any new lesions developing. The clinical significance of this residual malignant T-cell clone in mycosis fungoides remains to be elucidated.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Carmustine / therapeutic use
-
Humans
-
Male
-
Mycosis Fungoides / complications
-
Mycosis Fungoides / drug therapy
-
Mycosis Fungoides / pathology*
-
Neoplasm, Residual / etiology*
-
Neoplasm, Residual / metabolism
-
Neoplasm, Residual / pathology*
-
Pigmentation Disorders / complications
-
Pigmentation Disorders / pathology*
-
Polymerase Chain Reaction
-
Receptors, Antigen, T-Cell, gamma-delta / metabolism
-
Remission Induction
-
Skin Neoplasms / complications
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / pathology*
-
Skin Pigmentation
Substances
-
Antineoplastic Agents, Alkylating
-
Receptors, Antigen, T-Cell, gamma-delta
-
Carmustine